New anti-tubercular agents targeting intracellular bacteria
Active Project Grant Awarded Last action
- Award ID
- R01AI173110
- Recipient
-
Liverpool School Of Tropical Medicine UEI CL8TKXCL1UZ7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,630,201
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 48% complete
- Place of performance
- Great Britain, United Kingdom
Award details come from USAspending.gov.
Description
- Abstract
- Tuberculosis remains a major global health burden with ~1.6 million deaths in 2021 and a latently-infected population of billions. Mycobacterium tuberculosis, the causative agent, is a sophisticated pathogen which can persist for decades in the human host and which requires lengthy treatment for cure with multiple antibiotics. One of the features of m. Tuberculosis is its ability to survive and replicate inside human cells, including macrophages, one of the normal host defense mechanisms against infection. Intracellular bacteria are a specific population which can be hard to kill, in part due to the requirement that molecules enter eukaryotic cells, and in part due to the different physiological state in which the bacteria persist. Increasing evidence points to a higher level of antibiotic tolerance in intracellular bacteria, as well as increased heterogeneity. In order to identify new drugs which can shorten therapy, we focused on the identification of novel anti-tubercular agents which are active against intracellular bacteria. We identified a number of scaffolds which inhibit mycobacterial intracellular replication using a high content screen to monitor bacterial and eukaryotic cell survival simultaneously. From these, we selected high priority series with attractive properties for further evaluation. The overall aims of this proposal are to (i) evaluate a high priority chemical series with intracellular activity, (II) identify the target and mechanism of action of this novel series and (III) determine the best companion agents for a new regimen. The major outcome will be a molecule series with a known mechanism of action with in vivo validation ready for lead optimization.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$866,250 | |
| Amendment | $866,250 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $493,309 | |
| Amendment | $493,309 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $931,143 | |
| Amendment | $93,532 | |
| Amendment | $93,532 | |
| Amendment | $841,792 | |
| Amendment | $841,792 | |
| Original award | $841,792 |
Show all 15
Quick answers
Who received award R01AI173110?
R01AI173110 was awarded to Liverpool School Of Tropical Medicine by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 21, 2024.
How much is award R01AI173110 worth?
$4,630,201 has been obligated on R01AI173110.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award